Mitoxantrone;Mitoxantrona

Neurologia

Volumn 18, Issue 6, 2003, Pages 318-323

  Pericot, Imma ^a,b   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Unidad de Neuroinmunologia Clinica   (Spain)

Author keywords

Mitoxantrone; Multiple Sclerosis; Treatment

Indexed keywords

MITOXANTRONE;

ALOPECIA; AMENORRHEA; ANEMIA; CARDIOTOXICITY; CONSTIPATION; DIARRHEA; DISABILITY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GONAD DYSFUNCTION; GRANULOCYTOPENIA; HEADACHE; HEART ARRHYTHMIA; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LYMPHOCYTE COUNT; MALE; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NAUSEA; RELAPSE; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; SINUSITIS; T LYMPHOCYTE; URINARY TRACT INFECTION; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MITOXANTRONE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 0043067012     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. Supression of B lymphocyte function. J Immunol 1986;137:727-32.
2. Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS. Supression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985;35:35-42.
3. Lublin DE, Lavasa M, Viti C, Knobler RL. Supression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987;45:122-8.
4. Gonsette RE, Demonthy L. Immunosupression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990;40(Suppl 1):261.
5. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96-102.
6. Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman M, et al. An opel-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43:1401-6.
7. Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995;37:113-9.
8. De Castro S, Cartoni D, Millefiorini E, Funaro S, Gasperini C, Morino S, et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995;35:627-32.
9. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-9
10. Bastianello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994;21:266-70.
11. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:12-118.
12. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized multicentre trial. Lancet 2002;360:2018-25.
13. Weiss RB. Mitoxantrone: its development and role in clinical practice. Oncology 1989;3:135-41.
14. Unverferth DV, Bashore TM, Magorien RD, Fetters JK, Neidhart JA. Histologic and functional characteristics of human heart after mitoxantrone therapy. Cancer Treat Symp 1984;3:47-53.
15. Edan G, Brochet B, Clanet M, Clavelou P, Confavreux C, Debouverie M, et al. Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Multiple Sclerosis 2001; 7:14.
16. Meistrich ML, Wilson G, Mathur K, Fuller LM, Rodriguez MA, McLaughlin P, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol 1997;15:3488-95.
17. Vicari AM, Ciceri F, Folli F. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998;12:441-2.
18. Edan G, Brochet B, Brassat D, Clanet M, Clavelou P, Confavreux C, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients. Neurology 2002;58 (Suppl 3):168.